P48.12 A Meta-Analysis of ICI +EP Vs. EP for Untreated Extensive SCLC Using GRADE System Approach for Certainty in the Evidence

Etoposide plus platin (EP) have been the standard of care for treating extensive SCLC. Adding Immune CheckPoint inhibitors (ICI) has emerged as a new strategy; however, the magnitude of clinical benefit remains controversial for their use. We conducted a critical appraisal using a partially contextualized GRADE ( Grading of Recommendations, Assessment, Development and Evaluations) approach.